Post-Market Clinical Follow up Studies

by | Aug 23, 2019 | EU, Medical Devices, Regulatory, Requirements

Clinical evidence is required to assure the safety and efficacy of a medical device for intended use pre-market. After an appropriate risk-benefit analysis, the device may still be placed on the market with the residual risk. The questions about residual risk can be answered by conducting a post-market clinical study to assess the risk. A post-market clinical follow-up study is just one form of the many ways a company may decide to conduct post-market surveillance.

Circumstances that may result in the need for post-market clinical follow-up studies include, for example:1

  • Innovation, e.g., where the design of the device, the materials, the principles of operation, the technology or the medical indications are novel;
  • A new indication or claim has been approved;
  • Significant changes to device design or labeling;
  • Higher risk classification;
  • Higher risk anatomical locations;
  • The severity of disease/treatment challenges etc.

The elements of a post-market clinical follow-up study include:1

  • A clearly stated objective(s);
  • A scientifically sound design with an appropriate rationale and statistical analysis plan;
  • A study plan; and
  • Implementation of the study according to the plan, and analysis of the data and appropriate conclusion(s)

The study should be conducted in compliance with the plan, containing data analysis that draws conclusions on the residual risk, safety, and efficacy of the device by someone with appropriate expertise. Information concerning serious incidents identified during the study should be reported to the regulatory authorities.

The conclusions derived from the post-market clinical study may result in the need to open a CAPA, making changes to the labeling or IFU, changes to the manufacturing process, changes to the device design, etc.

A robust post-market surveillance program is a requirement set forth in the EU MDR. EMMA International can help you with all your EU MDR compliance needs.

Please refer to our EU MDR webpage: https://emmainternational.com/eu-mdr/.  Call us at 248-987-4497 or email us at info@emmainternational.com.


1GHTF (Feb 2010) Post-Market Clinical Follow-Up Studies retrieved on 08/21/2019 from http://www.imdrf.org/docs/ghtf/final/sg5/technical-docs/ghtf-sg5-n4-post-market-clinical-studies-100218.doc

 

Nikita Angane

Nikita Angane

Solutions Delivery Specialist - Ms. Angane is a Bioengineering graduate with experience in medical device commercialization, product development, quality system compliance and regulatory affairs. Her portfolio includes working on medical devices, combination products, and pharmaceuticals. As a Solutions Delivery Specialist at EMMA International, she offers her expertise to help our clients achieve an effective and sustainable quality system, and develop regulatory strategies for market access and compliance of new products in the US and international markets. Ms. Angane earned a Bachelor of Engineering in Biomedical Engineering from the University of Mumbai, India and an M.S. in Bioengineering from University of Illinois at Chicago.

More Resources

FDA Adverse Event Reporting 

FDA Adverse Event Reporting 

When reporting an Adverse Event to the Food and Drug Administration (FDA) the best method is to utilize the FDA Adverse Event Reporting System (FAERS). FAERS is a database that contains adverse event reports, product quality complaints that led to an adverse event, and medication error reports1. All FAERS reports are easily accessible to the public. 
De Novo Classification

De Novo Classification

A device can be registered for the De Novo pathway if there is evidence of the safety and effectiveness of the device and there is not a previously legally marketed predicate device1. When determining if your device can go through the De Novo process there are two pathways available to determine the device classification.
Abbreviated 510k submission

Abbreviated 510k submission

There are three types of 510K, Premarket Notifications, which can be submitted to the Food and Drug Administration (FDA) traditional, abbreviated, and special. Abbreviated and Special 510K submissions can be utilized when the submissions meet the certain factors presented by the FDA. When submitting an abbreviated 510K the submission must include the elements that are identified in 21CFR 807.87 for the information required in a premarket notification submission.

Ready to learn more about working with us?

Pin It on Pinterest

Share This